Jazz Pharmaceuticals (JAZZ) News Today

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 29,500 shares of the specialty pharmaceutical company's stock, v

Vanguard Group Inc. boosted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,448,689 shares of the specialty pharmaceutical company's stock after purchasi

Jazz Pharmaceuticals (NASDAQ:JAZZ) will be releasing earnings after the market closes on Wednesday, July 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=609773)

Ontario Teachers Pension Plan Board reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 49.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,967 shares of the specialty

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 25.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 33,219 shares of the specialty pha

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 33.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 477,564 shares of the specialty phar

Swiss National Bank trimmed its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 179,100 shares of the specialty pharmaceutical company's stock af

Russell Investments Group Ltd. raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 264,473 shares of the specialty pharmaceutical compa

Concurrent Investment Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 5,824 shares of the specialty pharmaceutical com

LSV Asset Management grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,380,858 shares of the specialty pharmaceutical comp

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating

John G Ullman & Associates Inc. bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,150 shares of the specialty phar

Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 12-Month Low at $99.74

Mirae Asset Global Investments Co. Ltd. reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 74,959 shares of the specialty pharmaceutic

Van ECK Associates Corp lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 33.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,693 shares of the specialty pharmaceutical company's

Kovack Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 88.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,599 shares of the specialty pharmaceutica

Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 52-Week Low on Analyst Downgrade

UBS Group lowered their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating on the stock in a research note on Tuesday.

StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday.

Goldman Sachs Group Inc. lowered its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 21.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 238,522 shares of the spe

Vanguard Group Inc. cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 0.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,363,748 shares of the specialty pharmaceutical company's stock after selling 15,305 share

Perpetual Ltd raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 54.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 475,018 shares of the specialty pharmaceutical comp

Needham & Company LLC reduced their price objective on Jazz Pharmaceuticals from $222.00 to $210.00 and set a "buy" rating on the stock in a research report on Thursday.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Down to $112.68

Los Angeles Capital Management LLC trimmed its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 34.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 201,261 shares of th

Centre Asset Management LLC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 70,381 shares of the specialty pharmaceutica

Brevan Howard Capital Management LP bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 12,556 shares of the specialty pharmaceutical company's stock, valued at approximately $1

Avidity Partners Management LP lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 38.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 489,119 shares of the specialty pharmaceutical

Strategic Global Advisors LLC lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 40.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,489 shares of the specialty pharmaceutical company's

Seven Eight Capital LP acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,529 shares of the specialty pharmaceutic

First National Bank of Omaha lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 16.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 37,953 shares of the specialty pharmaceutical com

Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Up 4.3%

The Manufacturers Life Insurance Company raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 104.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 279,428 shares of the sp

Armistice Capital LLC increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 108.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 651,626 shares of the specialty pharmaceutical compa

The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research note on Wednesday. They set a "buy" rating and a $169.00 target price for the company.